Poly(polyol sebacate) Elastomers as Coatings for Metallic Coronary Stents.
Navarro L., Mogosanu DE., de Jong T., Bakker AD., Schaubroeck D., Luna J.
Laboratory Study, published in Macromol Biosci (2016) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Macromol Biosci (2016)
- Country
- Germany
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 27500500
- DOI
- 10.1002/mabi.201600105
- Citations
- 2
Abstract (original English)
Biocompatible polymeric coatings for metallic stents are desired, as currently used materials present limitations such as deformation during degradation and exponential loss of mechanical properties after implantation. These concerns, together with the present risks of the drug-eluting stents, namely, thrombosis and restenosis, require new materials to be studied. For this purpose, novel poly(polyol sebacate)-derived polymers are investigated as coatings for metallic stents. All pre-polymers reveal a low molecular weight between 3000 and 18 000 g mol -1 . The cured polymers range from flexible to more rigid, with E-modulus between 0.6 and 3.8 MPa. Their advantages include straightforward synthesis, biodegradability, easy processing through different scaffolding techniques, and easy transfer to industrial production. Furthermore, electrospraying and dip-coating procedures are used as proof-of-concept to create coatings on metallic stents. Biocompatibility tests using adipose stem cells lead to promising results for the use of these materials as coatings for metallic coronary stents.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.